QuantCapitol. Congressional Trading Intelligence

Updated 2026-11-05 17:03 UTC · Public disclosure record

ANGOTICKER

Angiodynamics Inc.

INSUFFICIENT DATA stock

Congress has disclosed 2 buys and 2 sells of ANGO (Angiodynamics Inc.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.

Activity Congressional Activity

2
Buy
2
Sell
+0
Net
1
Active politicians
Price & congressional trades
Buy Sell

Fundamentals · FY2027 Valuation

Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for —. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.

P/B
3.08
no sector median
how it's calculated
P/B = price ÷ book value per share
$11.99 ÷ $3.90 = 3.08
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
EV/EBITDA
-34.53
no sector median
how it's calculated
EV/EBITDA = (market cap + net debt) ÷ EBITDA — net cash lowers EV
($0.5B − $0.0B net cash) ÷ $-0.0B = $0.5B ÷ $-0.0B = -34.53
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.

4 trades Recent Congressional Trades

Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.

PoliticianChamberTypeOwnerDateDisclosure lagPrice move
in that
window
AmountScoreSource
Debbie Wasserman Schultz House SELL Self 2025-07-16 0 days 0.0% $1K–$15K 17.0 ↗ filing
Debbie Wasserman Schultz House BUY Child 2025-06-27 1 days 0.0% $1K–$15K 24.4 ↗ filing
Debbie Wasserman Schultz House SELL Child 2016-11-08 0 days — $1K–$15K 40.4 ↗ filing
Debbie Wasserman Schultz House BUY Child 2016-04-27 0 days — $1K–$15K 75.9 ↗ filing

Corporate insiders · SEC Form 4 Insider Activity

What the company's own officers and directors did in ANGO — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →

0
Congress trades with insider convergence
0
…with insider divergence
13
Insider open-market trades

Of the congressional trades in ANGO, 0 coincided with corporate insiders moving the same way within 60 days, and 0 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.

DateInsiderRoleTypeSizeSource
2026-10-29 Trowbridge Stephen A C-suite SELL $290K ↗ EDGAR
2026-10-28 Trowbridge Stephen A C-suite SELL $21K ↗ EDGAR
2026-07-30 Nighan Warren JR Other SELL $344K ↗ EDGAR
2025-10-21 Weiss Lawrence T C-suite BUY $118K ↗ EDGAR
2025-10-13 Trowbridge Stephen A C-suite BUY $10K ↗ EDGAR
2025-10-09 Clemmer James C C-suite BUY $112K ↗ EDGAR
2025-01-16 Nighan Warren JR Other SELL $50K ↗ EDGAR
2024-10-10 Nighan Warren JR Other BUY $608 ↗ EDGAR
2024-10-08 Trowbridge Stephen A C-suite BUY $10K ↗ EDGAR
2024-10-07 Clemmer James C C-suite BUY 10b5-1 $121K ↗ EDGAR
2024-10-07 Nighan Warren JR Other BUY $5K ↗ EDGAR
2024-04-08 Clemmer James C C-suite BUY $67K ↗ EDGAR
2023-01-31 Helsel Dave Other SELL $60K ↗ EDGAR

Combined timeline — Congress & insiders

Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.

DateWhoTypeSize
◆ insider 2026-10-29 Trowbridge Stephen A C-suite SELL $290K
◆ insider 2026-10-28 Trowbridge Stephen A C-suite SELL $21K
◆ insider 2026-07-30 Nighan Warren JR Other SELL $344K
◆ insider 2025-10-21 Weiss Lawrence T C-suite BUY $118K
◆ insider 2025-10-13 Trowbridge Stephen A C-suite BUY $10K
◆ insider 2025-10-09 Clemmer James C C-suite BUY $112K
Congress 2025-07-16 Debbie Wasserman Schultz SELL $1K–$15K
Congress 2025-06-27 Debbie Wasserman Schultz BUY $1K–$15K
◆ insider 2025-01-16 Nighan Warren JR Other SELL $50K
◆ insider 2024-10-10 Nighan Warren JR Other BUY $608
◆ insider 2024-10-08 Trowbridge Stephen A C-suite BUY $10K
◆ insider 2024-10-07 Clemmer James C C-suite 10b5-1 BUY $121K
◆ insider 2024-10-07 Nighan Warren JR Other BUY $5K
◆ insider 2024-04-08 Clemmer James C C-suite BUY $67K
◆ insider 2023-01-31 Helsel Dave Other SELL $60K
Congress 2016-11-08 Debbie Wasserman Schultz SELL $1K–$15K
Congress 2016-04-27 Debbie Wasserman Schultz BUY $1K–$15K

FAQ Common questions

How much has Congress traded ANGO?

2 disclosed buys and 2 sells of ANGO (Angiodynamics Inc.) appear in official congressional financial disclosures.

Is it legal for members of Congress to trade ANGO?

Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.

Where does this data come from?

Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.

About this data. Sourced from official House Clerk and Senate eFD financial disclosures (Senate via a maintained community mirror — see project documentation). Transaction amounts are reported as ranges, not exact figures. Interest scores, consensus labels, and backtested performance are proprietary analytical calculations based on public data and are not investment advice. Backtested performance is a hypothetical simulation, not actual portfolio performance.